Cargando…

New and emerging lipid-modifying drugs to lower LDL cholesterol

Cardiovascular disease (CVD) represents the leading cause of death worldwide. The role of low-density lipoprotein-cholesterol (LDL-C) in the pathophysiology of atherosclerosis and CVD has been well recognized. Statins are the standard of care for the management of hypercholesterolaemia, and their ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Kosmas, Constantine E, Pantou, Dafni, Sourlas, Andreas, Papakonstantinou, Evangelia J, Echavarria Uceta, Rogers, Guzman, Eliscer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565402/
https://www.ncbi.nlm.nih.gov/pubmed/34795777
http://dx.doi.org/10.7573/dic.2021-8-3
Descripción
Sumario:Cardiovascular disease (CVD) represents the leading cause of death worldwide. The role of low-density lipoprotein-cholesterol (LDL-C) in the pathophysiology of atherosclerosis and CVD has been well recognized. Statins are the standard of care for the management of hypercholesterolaemia, and their effectiveness in lowering LDL-C and reducing CVD risk in both primary and secondary prevention has been well established. However, several patients fail to attain optimal LDL-C goals or are intolerant to statins, especially at high doses. PCSK9 inhibitors, bempedoic acid, inclisiran, ANGPTL3 inhibitors, PPARβ/δ agonists and LXR agonists are novel or upcoming LDL-C-lowering agents that have shown promising beneficial results. This review aims to present and discuss the current clinical and scientific data pertaining to the new and emerging lipid-modifying LDL-C-lowering drugs.